A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group.

Author(s):  
R. Swaby ◽  
M. Wang ◽  
J. Sparano ◽  
K. Bhalla ◽  
N. Meropol ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document